Dexcom Receives FDA Clearance for G7 15 Day CGM
Dexcom announced it received FDA clearance for its G7 15 Day CGM for people over the age of 18 with diabetes. The G7 15 Day CGM is expected to launch in H2 2025, and the company noted it is working to ensure its new CGM is compatible with its current insulin pump partners at launch. Recall, in October 2024, Dexcom disclosed that it submitted the 15 Day for FDA approval (previous FENIX insight). Below, FENIX provides highlights and insights on the approval.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.